ArticleProceedings of the National Academy of Sciences of the United States of America1998
Antiatherogenic effects of the antioxidant BO-653 in three different animal models.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 89 citations in OpenAlex.
- The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases.Translational neurodegeneration · 2024Review
- Antioxidants in the Fight Against Atherosclerosis: Is This a Dead End?Current atherosclerosis reports · 2018Review
- Antioxidants in Translational Medicine.Antioxidants & redox signaling · 2015Review
- Do free radicals play causal role in atherosclerosis? Low density lipoprotein oxidation and vitamin E revisited.Journal of clinical biochemistry and nutrition · 2011Article
- Escherichia coli lipopolysaccharide administration alters antioxidant profile during hypercholesterolemia.Indian journal of clinical biochemistry : IJCB · 2009Article
- The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits.The Journal of clinical investigation · 1999Article
- At last, direct evidence that lipoxygenases play a role in atherogenesis.The Journal of clinical investigation · 1999Article
- Pharmacological basis of different targets for the treatment of atherosclerosis.Journal of cellular and molecular medicineReview
- Effects of antioxidants against atherosclerosis.Molecular and cellular biochemistryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antioxidants have been proposed to have antiatherogenic potential by their inhibition of low density lipoprotein (LDL) oxidation. Here, we report an antioxidant, BO-653 (2,3-dihydro-5-hydroxy-2, 2-dipentyl-4,6-di-tert-butylbenzofuran), designed to exhibit antioxidative potency comparable to that of alpha-tocopherol, but yet possess a high degree of lipophilicity comparable to that of probucol. BO-653 exhibits a high affinity for LDL and is well distributed in aortic vessels in vivo. In atherosclerosis models of rabbits and mice, BO-653 has been shown to be able to suppress the formation of atherosclerotic lesions without untoward side effects. Specifically, there was no reduction of high density lipoprotein levels. This antioxidant provides additional evidence in support of the oxidized-LDL hypothesis, and itself is a promising candidate antioxidant for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.